Answers are grounded in this paper and cite their sources.
In this treatment-refractory CM population, erenumab showed efficacy in a real-world setting similar to data from clinical trials. Tolerability was good, and no safety issues emerged. Erenumabis is a treatment option for CM patients who failed all first-line preventives in addition to BoNTA.
No takes yet. Share an insight, caveat, or question.
Raffaelli et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: